Baar, Switzerland – March 2026
Novocure announced positive topline results from its Phase 2 PANOVA-4 clinical trial evaluating Tumor Treating Fields (TTFields) therapy in combination with standard treatments for metastatic pancreatic cancer, highlighting encouraging efficacy and safety outcomes in one of the most aggressive and difficult-to-treat cancers. The study reinforces the potential of TTFields, a non-invasive, device-based therapy, to enhance outcomes when combined with immunotherapy and chemotherapy, marking a significant advancement in integrated oncology treatment strategies.
Innovative Combination Therapy Demonstrates Clinical Benefit
The PANOVA-4 study is an international, multi-center Phase 2 clinical trial designed to evaluate the safety and efficacy of TTFields therapy used alongside atezolizumab, gemcitabine, and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma. This approach integrates device-based therapy with immunotherapy and chemotherapy, representing a novel multi-modal treatment paradigm in oncology.
TTFields therapy works by delivering low-intensity alternating electric fields that disrupt cancer cell division, ultimately leading to tumor cell death while sparing healthy tissue. This mechanism makes it a complementary modality to systemic therapies, improving therapeutic effectiveness without adding significant systemic toxicity.
The positive topline results suggest that the combination therapy achieved meaningful disease control and promising survival outcomes, supporting further development of TTFields in metastatic pancreatic cancer. The study’s primary endpoint focused on disease control rate, with additional endpoints including overall survival, progression-free survival, and response rates, providing a comprehensive evaluation of clinical benefit.
Advertisement
Addressing High Unmet Need in Pancreatic Cancer
Pancreatic cancer remains one of the most lethal malignancies globally, with a five-year survival rate of approximately 13% and limited therapeutic advancements over recent decades. The aggressive nature of the disease and its resistance to conventional therapies make it a critical area for innovation in oncology drug development.
The PANOVA-4 trial builds on previous successes of TTFields in pancreatic cancer, including the Phase 3 PANOVA-3 study, which demonstrated improved overall survival when TTFields was combined with chemotherapy. These findings underscore the growing role of non-invasive, device-based therapies in improving outcomes for patients with advanced cancers.
By targeting cancer cells through biophysical mechanisms rather than traditional biochemical pathways, TTFields offers a unique therapeutic advantage, particularly in tumors with poor drug penetration such as pancreatic cancer. This innovation aligns with the broader shift toward precision medicine and combination treatment strategies in oncology.
Advancing Clinical Development and Future Outlook
The positive Phase 2 results position PANOVA-4 as a key step toward further clinical development, potentially supporting future late-stage trials and regulatory submissions. The study enrolled approximately 76 patients globally, reflecting its role as a pilot trial to validate efficacy and safety before larger confirmatory studies.
Novocure continues to expand its TTFields platform across multiple cancer indications, including glioblastoma, lung cancer, and pancreatic cancer, with ongoing efforts to integrate the technology into standard-of-care treatment regimens worldwide. The company’s strategy emphasizes combining TTFields with established therapies to maximize patient benefit and improve survival outcomes.
Overall, the PANOVA-4 trial highlights the growing importance of combination therapies, innovative treatment modalities, and global clinical development strategies in addressing unmet needs in oncology. As further data emerge and development progresses, TTFields therapy could play a transformative role in redefining treatment standards for metastatic pancreatic cancer, offering new hope for patients facing this challenging disease.
Source: Novocure press release
